| Autor: |
Andrew Xanthopoulos, Konstantinos Tryposkiadis, Filippos Triposkiadis, Kiyotaka Fukamachi, Edward G. Soltesz, James B. Young, Kathy Wolski, Eugene H. Blackstone, Randall C. Starling |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 14 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.119.015897 |
| Popis: |
Background Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure. Anticoagulation and antiplatelet therapies represent the standard of care to mitigate LVAD thrombosis. Phosphodiesterase type 5 inhibitors (PDE‐5is) exhibit hemodynamic, antiplatelet, and antithrombotic effects. Using a national registry, we examined the relationship of PDE‐5i use on thrombotic events in patients with continuous‐flow LVADs. Methods and Results We obtained data from 13 772 patients with continuous flow LVADs participating in a national registry. Patients implanted with primary LVADs from 2012 to 2017 were included in the analysis. The primary end point was a composite of LVAD thrombosis and ischemic stroke. Patients were analyzed according to any use of PDE‐5i after LVAD implantation (PDE‐5i group) versus no use after LVAD implantation (no PDE‐5i group). The primary end point was significantly lower in the PDE‐5i group compared with the no PDE‐5i group (hazard ratio [HR], 0.84; 95% CI, 0.77–0.91; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text